Related Experiment Videos
Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective
1Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115.
Insights
Angiotensin-converting enzyme (ACE) inhibitors are now cornerstone therapy for heart failure patients. Studies show these drugs improve outcomes in both symptomatic and asymptomatic left ventricular dysfunction.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Angiotensin-converting enzyme (ACE) inhibitors emerged as a novel hypertension treatment.
- Initially for severe hypertension, their use expanded due to clinical experience.
Purpose of the Study:
- Review key studies on ACE inhibitor efficacy.
- Document benefits in congestive heart failure and left ventricular dysfunction.
Main Methods:
- Review of clinical studies on ACE inhibitors.
- Analysis of patient outcomes in heart failure cohorts.
Main Results:
- ACE inhibitors are effective in symptomatic heart failure.
- Proven value in preventing heart failure development.
- Improved clinical outcomes in overt congestive heart failure.
Conclusions:
- ACE inhibitors are essential for managing heart failure.
- Considered cornerstone therapy for symptomatic heart failure patients.
- Valuable for preventing heart failure in left ventricular dysfunction.
Abstract:
Therapy with angiotensin-converting enzyme (ACE) inhibitors was developed approximately 15 years ago as a novel therapeutic approach to hypertension. Although ACE inhibitor therapy was initially reserved for patients with severe hypertension, extensive clinical experience has broadened its use. These agents should now be considered as cornerstone therapy for patients with symptomatic heart failure and are of proved value in preventing the development of this syndrome. This article reviews the key studies that have documented the efficacy of ACE inhibitors in improving clinical outcome for patients with overt congestive heart failure, as well as for those with asymptomatic left ventricular dysfunction.